drugset / Trial / NCT00648622
Fed Study of Carvedilol Tablets 12.5 mg to Coreg® Tablets 12.5 mg
RandomizedCrossoverOpen-labelOther
Summary
The objective of this study was to investigate the bioequivalence of Mylan's carvedilol 12.5 mg tablets to GSK's Coreg® 12.5 mg tablets following a single, oral 12.5 mg (1 x 12.5 mg) dose administered under fed conditions.
Timeline
- Start
- 2004-04
- Primary completion
- 2004-04
- Completion
- 2004-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carvedilol | Other / unclassified | 12.5 mg | Oral |
Indications
No indication recorded.